Efficacy and safety of adding immune checkpoint inhibitors to standard chemotherapy or chemoradiotherapy for advanced or recurrent cervical cancer: a meta-analysis.

Front Immunol · 2026 · PMC12999943 · PMID 41869324

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

failed to reach statistical significanceno p-value reported

In subgroup analyses, this PFS advantage failed to reach statistical significance in the Asian patients (HR = 0.776, 95% CI: 0.473-1.272; 95% PI: 0.005-128.612) and among patients with a PD−L1 combined positive score (CPS) <1 (HR = 0.809, 95% CI: 0.561-1.165; 95% PI: 0.076-8.619).

also in 6,035 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.